Skip to main content

Are guidelines on use of colony-stimulating factors in solid cancers flawed?

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract

In cancer care in Australia, we are very reliant on an array of expensive pharmaceuticals. Our use of these treatments is often based on multinational or foreign clinical studies. Oncologists are, to varying degrees, reliant on how the studies are interpreted by the writers of journal editorials, clinical guidelines and opinion pieces. Therefore it is important that these guidelines are balanced and evidence based.

We have examined in detail one of the most influential and wide ranging clinical guidelines used in oncology, The American Society of Clinical Oncology (ASCO) 2006 Update of Recommendations for the use of White Blood Cell Factors: An Evidence-Based Clinical Practice Guideline. We have discussed in detail some of the controversial recommendations in this guideline and have exposed what we believe are some flaws in these recommendations.

We would urge that we continue to be rigorous in our oversight of international research agendas and international clinical guidelines in the future.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: clinical guideline; colony-stimulating factor; independent overview

Document Type: Research Article

Affiliations: The Cancer Council Australia, Sydney, New South Wales, Australia

Publication date: 2009-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more